Replies to post #22 on Atea Pharmaceuticals Inc (AVIR)

[DewDiligence]

The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

https://clinicaltrials.gov/ct2/show/NCT04575597